Prophylactic intravitreal injection of aflibercept for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy: A randomized controlled trial

IntroductionThe aim of this study was to assess the effects of preoperative intravitreal aflibercept (IVA) injection on the incidence of postoperative vitreous hemorrhage (VH) after vitrectomy for proliferative diabetic retinopathy (PDR).MethodsThis study involved a prospective, randomized clinical...

Full description

Saved in:
Bibliographic Details
Main Authors: Jinfeng Qu (Author), Xiuju Chen (Author), Qinghuai Liu (Author), Fang Wang (Author), Mingxin Li (Author), Qiong Zhou (Author), Jin Yao (Author), Xiaoxin Li (Author)
Format: Book
Published: Frontiers Media S.A., 2023-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_a4f958e3039d4c8591f8bc83b75a32a1
042 |a dc 
100 1 0 |a Jinfeng Qu  |e author 
700 1 0 |a Xiuju Chen  |e author 
700 1 0 |a Qinghuai Liu  |e author 
700 1 0 |a Fang Wang  |e author 
700 1 0 |a Mingxin Li  |e author 
700 1 0 |a Qiong Zhou  |e author 
700 1 0 |a Jin Yao  |e author 
700 1 0 |a Xiaoxin Li  |e author 
700 1 0 |a Xiaoxin Li  |e author 
245 0 0 |a Prophylactic intravitreal injection of aflibercept for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy: A randomized controlled trial 
260 |b Frontiers Media S.A.,   |c 2023-01-01T00:00:00Z. 
500 |a 2296-2565 
500 |a 10.3389/fpubh.2022.1067670 
520 |a IntroductionThe aim of this study was to assess the effects of preoperative intravitreal aflibercept (IVA) injection on the incidence of postoperative vitreous hemorrhage (VH) after vitrectomy for proliferative diabetic retinopathy (PDR).MethodsThis study involved a prospective, randomized clinical trial. One hundred twenty-eight eyes of 128 patients of PDR who underwent pars plana vitrectomy (PPV) were enrolled. Sixty-four eyes were assigned randomly to either the IVA group (IVA injection 1 to 5 days before PPV) or the control group (no IVA injection). The primary outcome was the incidence of VH at 1 month after PPV. Secondary outcome measures were best-corrected visual acuity (BCVA) changes from baseline to at 1 week, 1 month, 2 months, and 3 months after surgery.ResultsThe VH incidences in the IVA group and the control group were 14.8 and 39.3% at week 1, 8.6 and 31.7% at month 1, 11.7 and 30.5% at month 2, and 8.6 and 30.5% at month 3, respectively. Intergroup differences showed a significantly decreased VH rate in the IVA group compared with that in the control group at week 1, month 1, and month 3 (p = 0.021, 0.006, and 0.047, respectively). Compared to the baseline, neither the mean BCVA nor the BCVA change in the Logarithm of the Minimum Angle of Resolution (logMAR) scale did differ significantly between the two groups at each visit point. There are a greater number of eyes with BCVA improvement of more than 2 logMAR in the IVA group than in the control group at week 1 (8 vs. 2, p = 0.048).ConclusionsThis study found that the adjunctive use of preoperative IVA reduces early and late postoperative VH in vitrectomy for PDR. 
546 |a EN 
690 |a aflibercept 
690 |a vitreous hemorrhage 
690 |a vitrectomy 
690 |a diabetic retinopathy 
690 |a post-vitrectomy hemorrhage 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Frontiers in Public Health, Vol 10 (2023) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fpubh.2022.1067670/full 
787 0 |n https://doaj.org/toc/2296-2565 
856 4 1 |u https://doaj.org/article/a4f958e3039d4c8591f8bc83b75a32a1  |z Connect to this object online.